Carl’s Jr.® and Hardee’s® Unveil National ‘Feed Your Happy’ Campaign Featuring Brand Icon Happy Star

FRANKLIN, Tenn.–(BUSINESS WIRE[1])–CKE, the parent company of Carl’s Jr.[2]® and Hardee’s[3]®, today announced the launch of their new nationally advertised “Feed Your Happy” brand campaign, in partnership with 72andSunny New York. The new campaign is designed to unlock an escape from mundane day-to-day experiences, and the challenges of “adulting” consumers know all too well – from surviving office meetings to...

READ MORE Carl’s Jr.® and Hardee’s® Unveil National ‘Feed Your Happy’ Campaign Featuring Brand Icon Happy Star

Trial setback strikes blow to Sage antidepressant ambitions

Dive Brief: An experimental antidepressant developed by Sage Therapeutics did not meet the main goal of a closely watched study, sending shares in the biotech spiraling downward and undercutting the company’s hopes of proving a clear-cut benefit for the drug.  A high dose of the treatment, called SAGE-217, appeared to initially reduce depressive symptoms more than placebo. But, by day...

READ MORE Trial setback strikes blow to Sage antidepressant ambitions

Death of the Christmas party? Why companies must avoid a joyless Noël

A joyless press release landed in my inbox last week. According to offices.co.uk[1], a provider of serviced offices and flexible workplaces, 61% of managers and directors are planning to spend less this year on their office Christmas parties. Twelve per cent said they were cancelling their Christmas party altogether, according to the company’s survey of mostly London businesses. Bah humbug, we...

READ MORE Death of the Christmas party? Why companies must avoid a joyless Noël

FDA approves Spravato, a fast-acting antidepressant nasal spray

The first new class of antidepressant drugs in more than three decades was approved in March when the U.S. Food and Drug Administration (FDA) fast-tracked esketamine, the chemical cousin of illegal street drug ketamine, to prescribe to patients with treatment-resistant depression. Developed by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, esketamine is marketed under the name Spravato and dispensed as a...

READ MORE FDA approves Spravato, a fast-acting antidepressant nasal spray